Treatment with JQ1, a BRD4 inhibitor, restores PINK1/Parkin-mediated mitophagy and attenuates HFD-induced diabetic cardiomyopathy, highlighting the regulatory role of BRD4 in this pathway [110]. Here, BRD4 is linked to diabetic cardiomyopathy.